PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a U.S.-based biotechnology company focused on developing cellular therapies for cancer using its proprietary Cell-in-a-Box® live-cell encapsulation platform. The company’s current product candidate family includes CypCaps™, with development centered on therapies for pancreatic cancer and other oncology indications.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueEncapsulated live-cell technologies designed to activate cancer prodrugs near tumors.
CypCaps™ and related encapsulated-cell product candidates for pancreatic cancer.
Research, assay development, and nonclinical work supporting IND-enabling studies.
Customers
PharmaCyte Biotech does not currently sell commercial products; its primary counterparties are regulators, clinical investigators, consultants, and potential future licensing partners. If its product candidates are approved, the intended end customers would be oncology patients treated through hospitals, cancer centers, and pharmaceutical commercialization partners.
FDA and comparable agencies review INDs, clinical holds, and trial packages for the company's oncology programs.
Hospitals, physicians, and research sites conduct preclinical and clinical studies for LAPC and related programs.
Large pharmaceutical companies may license approved product candidates for commercialization.
Patients with pancreatic cancer and other cancers would be treated if the therapies reach market.
Strategy
The company’s strategy is to advance its Cell-in-a-Box® platform through regulatory clearance and clinical development for pancreatic cancer, especially LAPC. It also appears to be reassessing its technology and partner dependencies while preserving optionality for licensing or collaboration if a product candidate reaches approval.
Regulatory clearance is required before the planned pancreatic cancer trial can proceed.
The platform is the core technology underpinning the company's product candidates.
The company may need a licensing or partnership route to bring any approved therapy to market.
Geography
The company is headquartered in Las Vegas, Nevada and is incorporated in the United States. Its business is primarily U.S.-based, with regulatory and clinical development activities tied to U.S. healthcare and FDA oversight; any future commercialization could also involve foreign regulators such as the EMA.
Risks
PharmaCyte Biotech faces the typical risks of an early-stage biotech company: clinical failure, regulatory delays, manufacturing complexity, and dependence on external capital. Company-specific risks include the FDA clinical hold, dependence on SG Austria-related technology and know-how, and potential IP disputes or expirations that could impair the platform.
- FDA clinical hold on the LAPC programImpact: HighLikelihood: High
The planned pancreatic cancer trial cannot proceed until requested studies and responses are accepted.
Exposure: Lead product candidate development
- Clinical and preclinical failureImpact: HighLikelihood: High
Oncology programs may fail to show safety, efficacy, or manufacturability in trials.
Exposure: Product candidate pipeline
- Dilution and financing riskImpact: HighLikelihood: High
The company expects to need additional capital and may rely on equity, debt, or partnerships.
Exposure: Corporate funding
- Dependence on SG Austria technology and know-howImpact: HighLikelihood: Medium
The company disclosed that licensed patents have expired and know-how resides with SG Austria.
Exposure: Core platform access
- Biologics manufacturing complexityImpact: MediumLikelihood: Medium
Cell-based products require specialized facilities, quality controls, and validated processes.
Exposure: Cell encapsulation and fill-finish steps
- Nasdaq listing compliance riskImpact: MediumLikelihood: Medium
A sustained low share price could lead to delisting and reduce liquidity for investors.
Exposure: Public market access
Accounting
Judgemental itemsManagement must estimate fair values for instruments that may not have observable market prices.
Impact: Can affect reported gains, losses, and balance sheet values
The company tests intangible assets for impairment when events suggest value may have declined.
Impact: Can create non-cash charges and reduce asset carrying values
Option grants and changes in fair value assumptions influence compensation expense.
Impact: Can materially affect operating expenses and net loss
Some development and advisory services are provided by related parties and consultants.
Impact: Requires careful disclosure and expense classification
With no commercial sales, reported results depend on R&D and G&A spending patterns.
Impact: Quarterly comparability is driven by project timing rather than sales seasonality
Similar listed companies
Publicly listed companies with a comparable business focus.
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
MaxCyte, Inc
MXCT · Services-Commercial Physical & Biological Research
MaxCyte is a cell-engineering tools and platform company built around its Flow Electroporation technology and ExPERT instrument family.
Greenwich LifeSciences, Inc.
GLSI · Pharmaceutical Preparations
Precigen, Inc
PGEN · Pharmaceutical Preparations
Last updated: 24/09/2026